Zum Hauptinhalt springen

CSL Behring Signs First Commercial Agreement in Austria to Fund Haemophilia B Gene Therapy

Important European milestone for hemophilia B patients!


With this agreement in place, eligible patients in Austria with severe and moderately severe haemophilia B can be treated at the Haemophilia Comprehensive Care Centre at the Medical University of Vienna, the first HUB-centre in the country.

Hemgenix Newsbild

Link to international press release

mehr erfahren